Items Tagged ‘Recurrent Melanoma’

November 9th, 2015

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma

By

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin cancer to spread from its site of origin to other sites in the […]

View full entry

Tags: Melanoma, News, Recurrent Melanoma, Stage III Melanoma


May 1st, 2015

Melanoma Drug T-VEC Receives Recommendation for FDA Approval

By

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to move forward with approval process.[1] The recommendation for approval is based on findings from a Phase III clinical trial in which […]

View full entry

Tags: fda, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, T-VEC


February 2nd, 2015

Coffee May Decrease Risk of Melanoma Skin Cancer

By

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been associated with a reduction in the risk of various cancers however the current study is the first to show a reduction […]

View full entry

Tags: coffee, Melanoma, melanoma prevention, News, Recurrent Melanoma, Stage IV Melanoma


December 23rd, 2014

FDA Approves Nivolumab for Advanced Melanoma

By

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab (Yervoy) and, for melanoma patients whose tumors express the BRAF V600 mutation, for use after treatment with ipilimumab […]

View full entry

Tags: fda, Melanoma, News, nivolumab, opdivo, PD-1, Recurrent Melanoma, Stage IV Melanoma


December 8th, 2014

Yervoy® May be Beneficial in Uveal Melanoma

By

The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR) 2014 International Congress, in Zurich, Switzerland. Uveal melanoma is the most common cancer of the eye in adults, and the […]

View full entry

Tags: ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, uveal melanoma, Yervoy


November 25th, 2014

PV-10 Injection is Promising Treatment of Melanoma Lesions

By

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal, which was originally used as an agent to stain necrotic tissue in the cornea. Its potential use in […]

View full entry

Tags: intralesional, Melanoma, News, pv-10, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Stages I-II Melanoma, subcutaneous


November 24th, 2014

New Information Helps Understanding Immunotherapy’s Successes—And Its Failures

By

(OMNI- CancerConnect) A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.  MSK was at the forefront of the clinical research that brought this CTLA-4 […]

View full entry

Tags: immunotherapy, ipilimumab, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, Yervoy


November 20th, 2014

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma

By

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously untreated patients. These results were recently published online in the New England Journal of Medicine.[1] Of the more than one million new diagnoses of skin cancer each year, […]

View full entry

Tags: immunotherapy, Melanoma, melaoma, News, nivolumab, PD-1, Recurrent Melanoma, Stage IV Melanoma


November 19th, 2014

Thin Melanomas Responsible for Many Melanoma Related Deaths

By

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted to evaluate whether the people dying from melanoma were mostly those who had avoided early detection and […]

View full entry

Tags: cancer prevention, Melanoma, News, Recurrent Melanoma, Screening/Prevention Melanoma, Stages I-II Melanoma


November 14th, 2014

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers

By

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin cancer are diagnosed each year.2 Rates of melanoma—the deadliest form of skin cancer—are on the rise,2 particularly […]

View full entry

Tags: anti-PD-1, basal cell, General Skin Cancer, keytruda, Melanoma, News, pembrolizumab, Recurrent Melanoma, Skin Cancer, Skin Cancer Overview, Stage III Melanoma, Stage IV Melanoma


November 12th, 2014

Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma

By

(CancerConnect) Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by Dana-Farber Cancer Institute scientists. Patients in the clinical trial who got the combined therapies also […]

View full entry

Tags: gm-csf, ipilimumab, Melanoma, News, Recurrent Melanoma, sargramostim, Stage IV Melanoma, Yervoy


October 13th, 2014

Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma

By

Nivolumab appears to be more active and safer than chemotherapy in patients with advanced melanoma who have received previous treatment. These findings were presented at the 2014 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, September 26–30.[1] Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve […]

View full entry

Tags: Melanoma, News, nivolumab, PD-1, Recurrent Melanoma, Stage IV Melanoma


October 8th, 2014

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000 people die of melanoma each […]

View full entry

Tags: Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, tafinalr, trametinib, zelboraf


October 2nd, 2014

BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials

By

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the more than one million new diagnoses of skin cancer each year, roughly 68,000 involve melanoma. More than 8,000 people die of melanoma each […]

View full entry

Tags: BRAF, cobimetinib, cobrim, mek, Melanoma, News, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma, vemurafenib, zelboraf


September 5th, 2014

Pembrolizumab Gets FDA Approval in Advanced Melanoma

By

The U.S. Food & Drug Administration (FDA) has granted approval to Merck’s new immunotherapy drug, Keytruda (pembrolizumab), for treating metastatic melanoma.   It is the first anti-PD-1 drug, aimed at re-energizing a patient’s protective immune response to cancer to have received FDA approval in the U.S. Of the more than one million new diagnoses of skin […]

View full entry

Tags: anti-PD-1, Melanoma, News, pembrolizumab, Recurrent Melanoma, Stage IV Melanoma